Saturday 17 October 2026
Export BGLC’s income statement to Excel — free account
BioNexus Gene Lab Corp.
BGLC Basic Materials Specialty Chemicals
BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS grew 64.7% and free cash flow grew 44.3%, each against the same quarter a year earlier.
1.20
0.02
−1.64%
Follow BGLC
| Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
206.86 | 206.86 | 206.86 | 485.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | 5 | 5 | 3 | 4 | 3 | 4 |
P/S ratio |
19.87 | 19.87 | 19.87 | 27.28 | 15.82 | 8.48 | 0.52 | 0.99 |
Altman Z-Score |
— | — | — | 93.92 | 49.38 | 29.56 | 2.05 | 6.34 |
Altman Z″-Score (non-manufacturers) |
17.24 | 12.86 | 6.11 | 7.71 | 6.60 | 7.50 | 5.59 | 13.32 |
P/FCF ratio |
141.55 | 141.55 | 141.55 | 60,756.12 | 347.51 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
242.71 | 242.71 | 242.71 | 754.73 | 362.74 | (105.90) | 22.76 | 7.63 |
Beneish M-Score |
— | (2.25) | 78.92 | (1.59) | (2.67) | (3.54) | (1.84) | (3.31) |
P/B ratio |
33.97 | 33.97 | 33.97 | 50.77 | 25.94 | 8.58 | 0.60 | 0.85 |
Price to Tangible BV |
33.97 | 33.97 | 33.97 | 50.77 | 25.94 | 8.58 | 0.60 | 0.85 |
EV/Sales |
19.63 | 19.63 | 19.63 | 27.12 | 15.63 | 7.89 | 0.08 | 0.46 |
EV/EBITDA |
162.54 | 162.54 | 162.54 | 311.34 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
404.51 | 404.51 | 404.51 | 39,394.09 | 309.61 | (42.28) | (0.34) | (1.85) |
EV/FCF |
139.83 | 139.83 | 139.83 | 60,404.27 | 343.33 | (39.08) | (0.31) | (1.81) |
Quick Ratio |
20.40 | 16.96 | 2.02 | 2.39 | 2.52 | 4.24 | 3.10 | 9.00 |
Current Ratio |
20.64 | 17.10 | 2.37 | 3.07 | 3.00 | 4.93 | 3.81 | 10.46 |
Net Debt/EBITDA |
(11.91) | 3.66 | (2.00) | (1.81) | 11.40 | 2.45 | 3.44 | 1.49 |
Debt/Assets |
3.81% | 3.66% | 0.35% | 0.13% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.04 | 0.04 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.09 | 2.01 | 1.36 | 1.19 | 0.97 | 0.87 | 0.75 |
Operating CF/Net income |
(10.34) | 0.88 | 0.51 | 0.01 | (1.55) | 0.69 | 1.31 | 0.62 |
Capex/Depreciation |
(0.98) | (0.24) | 10.30 | (0.03) | (0.51) | (1.38) | (1.48) | (0.22) |
| 0.00% | (18.64%) | 28.11% | 10.86% | (5.14%) | (32.21%) | (17.78%) | (35.24%) | |
| 0.00% | (17.10%) | 19.29% | 7.63% | (3.89%) | (26.11%) | (14.64%) | (30.32%) | |
ROIC |
11.53% | (55.87%) | 20.36% | 13.02% | (4.00%) | (43.47%) | (24.93%) | (40.51%) |
Return on Tangible Assets |
1.68% | (21.55%) | 17.10% | 11.64% | (6.44%) | (33.16%) | (22.83%) | (45.73%) |
Average Days of Receivables |
39.20 | 45.70 | 128.87 | 93.87 | 97.70 | 36.60 | 63.88 | 31.90 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.56% | 0.50% | 0.68% |
Selling, General and Administrative Expense of Revenue |
113.94% | 280.79% | 11.70% | 9.56% | 15.83% | 31.11% | 42.11% | 54.77% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.24% | 1.48% | 10.70% |
Graham Net Nets |
0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.08 | 1.07 | 0.66 |
Graham Number |
1.72 | 0.00 | 14.94 | 7.73 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
0.48% | 0.48% | 0.48% | 0.21% | (0.04%) | (3.17%) | (32.49%) | (40.43%) |
Free Cash Flow Yield |
0.71% | 0.71% | 0.71% | 0.00% | 0.29% | (2.38%) | (46.51%) | (25.57%) |
Revenue per Share |
0.38 | 0.18 | 13.29 | 9.37 | 7.58 | 0.62 | 5.34 | 4.00 |
Operating CF per Share |
(0.50) | (0.30) | 0.64 | 0.01 | 0.38 | (0.11) | (1.17) | (0.99) |
Capex per Share |
(0.07) | (0.02) | 1.22 | 0.00 | (0.04) | (0.01) | (0.13) | (0.02) |
Free Cash Flow per Share |
(0.57) | (0.32) | 1.87 | 0.00 | 0.35 | (0.12) | (1.30) | (1.01) |
Cash per Share |
2.28 | 1.19 | 3.25 | 1.49 | 1.47 | 0.37 | 2.46 | 2.18 |
Shareholders Equity per Share |
2.75 | 1.56 | 7.77 | 5.03 | 4.63 | 0.61 | 4.67 | 4.64 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.75 | 1.56 | 7.77 | 5.03 | 4.63 | 0.61 | 4.67 | 4.64 |
Free Cash Flow |
(0.31) | (0.23) | 1.60 | 0.01 | 0.50 | (1.97) | (2.32) | (1.88) |
Working Capital |
1.24 | 0.83 | 4.61 | 4.82 | 4.02 | 6.42 | 5.48 | 4.93 |
Capital Expenditures |
(0.04) | (0.01) | 1.05 | 0.00 | (0.05) | (0.15) | (0.23) | (0.04) |
Net Current Asset Value |
1.17 | 0.77 | 4.53 | 4.76 | 3.95 | 6.30 | 5.32 | 4.81 |
EV/EBIT |
175.52 | 175.52 | 175.52 | 343.27 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.19 | 0.10 | (0.09) | 0.00 | 0.01 | 0.02 | 0.02 | 0.01 |
Price to Operating Income |
177.68 | 177.68 | 177.68 | 345.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.12 | 0.17 | 0.06 | 0.07 | 0.07 | 0.07 | 0.10 | 0.11 |
Cash ROIC |
(11.03%) | (11.35%) | 16.86% | 0.06% | 5.66% | (12.65%) | (18.27%) | (14.82%) |
Accounts Receivable Turnover |
0.00 | 6.56 | 5.64 | 3.58 | 3.44 | 5.00 | 7.19 | 6.42 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 4.28 | 4.99 | 5.17 | 5.66 | 8.42 |
Inventory Turnover |
0.00 | 6.21 | 16.34 | 8.22 | 7.74 | 7.98 | 6.51 | 6.14 |
Average Days of Payables |
0.00 | 0.00 | 119.67 | 66.20 | 70.25 | 60.63 | 66.74 | 0.13 |
Days of Inventory on Hand |
30.42 | 39.02 | 44.39 | 50.06 | 36.91 | 49.20 | 61.65 | 38.96 |
Average Receivables |
— | 0.02 | 2.02 | 3.73 | 3.18 | 1.95 | 1.32 | 1.16 |
Average Payables |
— | — | — | 2.59 | 1.94 | 1.63 | 1.45 | 0.75 |
Average Inventory |
— | 0.01 | 0.59 | 1.35 | 1.25 | 1.06 | 1.26 | 1.03 |
Average Assets |
— | 1.44 | 5.67 | 9.84 | 9.16 | 10.07 | 10.92 | 9.84 |
Average Common Equity |
— | 1.32 | 3.89 | 6.92 | 6.92 | 8.16 | 8.99 | 8.47 |
Columns are period end dates